Interest in microbial therapeutics has grown substantially in the last few years. Backed by Big Pharma, investment and innovation in this space have been quite robust, making it one of the fastest growing biologics markets. Indeed, more than 120 microbiome therapeutic drugs are currently in development pipelines, aiming to reach the market in a few years. However, manufacturing remains one of the biggest bottlenecks.
This exclusive whitepaper identifies the current challenges the industry faces in defining manufacturing standards for microbiome therapeutic products, and the available opportunities to solve them, including:
- Background on manufacturing microbiome therapeutics
- Current challenges within data collection and sequencing
- Roles and relationships between pharmaceutical companies and regulatory bodies
- Strategies for defining manufacturing protocols
To read the whitepaper, just click on the image below.
